Trial Profile
A safety and efficacy study of brentuximab vedotin in combination with donor lymphocyte infusion for the treatment of relapsing hodgkin lymphoma after allogeneic stem cell transplantation.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jan 2016
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 23 Jan 2016 New trial record
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology